Abstract
After disease progression on EGFR tyrosine kinase inhibitor (TKI) therapy, patients with EGFR-mutated NSCLC who are then treated with platinum-based c......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
